Roche's Avastin approved in Japan for treatment of the most aggressive form of brain cancer

Roche today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Avastin (bevacizumab) for the treatment of malignant glioma, including newly diagnosed glioblastoma (GBM) in combination with radiotherapy and temozolomide chemotherapy, and as monotherapy for treatment of recurrent GBM and certain other types of high grade glioma following prior therapy.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news